Evidence map›Paper›PMID 38648251›Full record

ArticleChemMedChem2024

Lysophosphatidic Acid Receptor 1 (LPA

Wenjie Liu, Amr A K Mousa, Austin M Hopkins, Yin Fang Wu, Kelsie L Thu, Michael Campbell, Simon J Lees, Rithwik Ramachandran, Jinqiang Hou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Wenjie LiuDepartment of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada.
Amr A K MousaDepartment of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Austin M HopkinsDepartment of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada.
Yin Fang WuKeenan Research Centre for Biomedical Science at St. Michael's Hospital, Toronto, Ontario, Canada.
Kelsie L ThuKeenan Research Centre for Biomedical Science at St. Michael's Hospital, Toronto, Ontario, Canada.
Michael CampbellDepartment of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada.
Simon J LeesNorthern Ontario School of Medicine University, Thunder Bay, Ontario, Canada.
Rithwik RamachandranDepartment of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
Jinqiang HouDepartment of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada.ORCID https://orcid.org/0000-0003-4467-638X
Thunder Bay Regional Research Institute · CASt. Michael's Hospital · CAWestern University · CALakehead University · CANOSM University · CA

Funding

Canada Foundation for Innovation (CFI)Lakehead UniversityNatural Sciences and Engineering Research Council of Canada (NSERC)Ontario Research Fund (ORF)Thunder Bay Regional Health Research Institute
6 · The paper itself

Abstract

Metastasis is responsible for about 90 % of cancer deaths. Anti-metastatic drugs, termed as migrastatics, offer a distinctive therapeutic approach to address cancer migration and invasion. However, therapeutic exploitation of metastasis-specific targets remains limited, and the effective prevention and suppression of metastatic cancer continue to be elusive. Lysophosphatidic acid receptor 1 (LPA

Indexed as

Antineoplastic AgentsCell MovementReceptors, Lysophosphatidic AcidTriple Negative Breast NeoplasmsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMolecular StructureStructure-Activity RelationshipTriazolesAntineoplastic AgentsLPAR1 protein, humanReceptors, Lysophosphatidic AcidTriazolescancer metastasisLysophosphatidic acid receptor 1triple-negative breast cancer

Identifiers

PMID38648251
PMCPMC13494816
OpenAlexW4394995880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.